JAK inhibitors can suppress the IFN signaling in human dendritic cells, reduce CD80/CD86 expression and T-cell stimulation ability (39), and reduce the production of various inflammatory cytokines including IFN-γ (40) in SLE mice. Here, CD86 is linked to systemic lupus erythematosus.